SAN FRANCISCO & BOSTON--(BUSINESS WIRE)--Audax Private Equity (“Audax”) has completed its acquisition of the clinical services business of Avantor, Inc. (NYSE: AVTR) and, in close collaboration with the employees, has re-branded the business as Resonant Clinical Solutions (“Resonant” or “the Company”)..

。。

Resonant is comprised of three well-respected brands – EPL Archives, MESM, and Therapak. These long-standing brands, whose roots and lineage extend as far back as the 1970s, provide a comprehensive, quality-focused service offering to its pharmaceutical, biotechnology, contract research organization (CRO), and diagnostic laboratory customers.

共振由三个备受尊敬的品牌组成-EPL Archives、MESM和Therapak。这些历史悠久的品牌，其根源和血统可以追溯到20世纪70年代，为其制药，生物技术，合同研究组织（CRO）和诊断实验室客户提供全面的，以质量为重点的服务。

Beyond investing in the business and operations of Resonant, Audax will look to drive organic and inorganic growth to enhance the brands’ existing solution sets while adding complementary capabilities through M&A..

除了投资Resonant的业务和运营之外，Audax还将寻求推动有机和无机增长，以增强品牌现有的解决方案集，同时通过并购增加互补能力。

“We are grateful for Avantor’s stewardship and support of Resonant’s growth over the last seven years and are excited to support the Company in its next phase of growth as an independent platform in the outsourced clinical trial services sector,” said Stephen Weaver, Managing Director at Audax Private Equity.

Audax Private Equity董事总经理斯蒂芬·韦弗（Stephen Weaver）表示：“我们感谢Avantor在过去七年中对共振公司发展的指导和支持，并很高兴支持该公司作为外包临床试验服务部门的独立平台进入下一个发展阶段。”

“We have a plan in place to effect a seamless transition as Resonant.”.

“我们有一个计划来实现共振的无缝过渡。”

“We believe Resonant’s long-tenured customer relationships -- built on years of partnership with clients -- position the Company well to accelerate growth,” said David Wong, Partner at Audax Private Equity. “Increasing complexity of clinical trial services is driving pharma sponsors and CROs to outsource these services to specialists.

Audax Private Equity合伙人David Wong表示：“我们认为，共振长期与客户的关系建立在与客户多年合作的基础上，使公司能够很好地加速增长。”

Resonant’s solution set allows its clients to better manage this complexity and focus their energy on drug discovery and R&D.”.

共振的解决方案集使其客户能够更好地管理这种复杂性，并将精力集中在药物发现和研发上。”

Moelis & Company LLC served as financial advisor and Ropes & Gray LLP served as legal counsel to Audax Private Equity. J.P. Morgan Securities LLC served as exclusive financial advisor to Avantor and Arnold & Porter served as Avantor’s legal advisor.

Moelis&Company LLC担任财务顾问，Ropes&Gray LLP担任Audax Private Equity的法律顾问。J、 P.Morgan Securities LLC担任Avantor的独家财务顾问，Arnold＆Porter担任Avantor的法律顾问。

ABOUT AUDAX PRIVATE EQUITY

关于AUDAX私募股权

Headquartered in Boston, with offices in San Francisco, New York, and London, Audax Private Equity manages three strategies: its Flagship and Origins private equity strategies, seeking control buyouts in the core middle and lower middle markets, respectively, and its Strategic Capital strategy that provides customized equity solutions to PE-backed portfolio companies to help drive continued growth.

Audax Private Equity总部位于波士顿，在旧金山、纽约和伦敦设有办事处，负责管理三项战略：其旗舰和起源私募股权战略，分别在核心的中低端市场寻求控制权收购，以及其战略资本战略，为私募股权投资组合公司提供定制的股权解决方案，以帮助推动持续增长。

With approximately $19 billion of assets under management as of June 2024, over 270 employees, and 100-plus investment professionals, Audax has invested in more than 170 platforms and 1,300 add-on acquisitions since its founding in 1999. Through our disciplined Buy & Build approach, across six core industry verticals, Audax seeks to help portfolio companies execute organic and inorganic growth initiatives with the aim of fueling revenue expansion, optimizing operations, and significantly increasing equity value.

截至2024年6月，Audax管理着大约190亿美元的资产，拥有270多名员工和100多名投资专业人员，自1999年成立以来，Audax已经投资了170多个平台和1300多个附加收购。通过我们严格的购买和建造方法，跨越六个核心行业垂直领域，Audax寻求帮助投资组合公司执行有机和无机增长计划，以推动收入扩张，优化运营，并显着提高股权价值。

For more information, visit www.audaxprivateequity.com or follow us on LinkedIn..

有关更多信息，请访问www.audaxprivateequity.com或在LinkedIn上关注我们。

ABOUT RESONANT CLINICAL SOLUTIONS

关于共振临床解决方案

With over 850 employees, Resonant Clinical Solutions provides clinical trial and laboratory supply chain services to pharmaceutical and biotechnology companies, contract research organizations (CROs), and diagnostic laboratories. The Company operates 10 facilities across the US, UK, and Europe and maintains a global logistics and equipment services network that distinguishes the business as a partner of choice to help its clients manage complex and evolving supply chain needs..

共振临床解决方案拥有850多名员工，为制药和生物技术公司、合同研究组织（CRO）和诊断实验室提供临床试验和实验室供应链服务。该公司在美国、英国和欧洲运营着10家工厂，并维持着一个全球物流和设备服务网络，使该公司成为首选合作伙伴，以帮助其客户管理复杂且不断变化的供应链需求。